PreTT ApS (“PreTT”), a Copenhagen-based company developing a pioneering pretargeted radioligand therapy (RLT) platform, today announced a CEO transition to support the company’s strong momentum and next phase of growth.
By mutual agreement with the Board of Directors, Mr. Francesco Sergi‑Lindell has stepped down from his role as Chief Executive Officer and has departed the company. The Board thanks Mr. Sergi‑Lindell for his leadership and his important contributions in establishing PreTT’s foundation and early progress.
Effective now, Dr. Natalia Herrero Alvarez, previously R&D Director, has been appointed Chief Executive Officer. Dr. Herrero Alvarez has been at the center of PreTT’s scientific strategy and pipeline, and her appointment reflects the company’s confidence in its technology, trajectory, and long‑term ambitions.
“PreTT is entering a very exciting phase, with strong scientific momentum and a clear path to value‑creating milestones,” said Hans Schambye, M.D., Ph.D., Chairman of the Board of Directors. “On behalf of the Board, I would like to sincerely thank Francesco for his dedication and for building a solid platform for the company, and I am equally pleased to welcome Natalia as CEO; her deep understanding of our pretargeting platform, combined with her strategic insight and drive, uniquely positions her to lead PreTT through its next stage of growth.”
As R&D Director, Dr. Herrero Alvarez has played a key role in shaping PreTT’s RLT platform and advancing the company’s programs, bringing a combination of scientific excellence, execution focus, and leadership. The leadership transition is intended to ensure continuity while adding further momentum as PreTT advances its technology and prepares for future partnerships and development milestones.
About PreTT
PreTT is an innovative company based in Copenhagen, at the BioInnovation Institute (BII), focused on revolutionizing cancer treatment with its pioneering pretargeted radioligand therapy (RLT) platform. PreTT’s breakthrough pretargeting technology enhances the power of monoclonal antibodies (mAbs) in RLT, addressing challenges such as slow accumulation in tumors and delayed excretion from the body, which can lead to radiotoxicity in healthy tissues. The platform has the potential to significantly improve the precision and effectiveness of cancer treatment compared with conventional approaches.
For more information, please contact:
Natalia Herrero Alvarez, CEO
Email: natalia.herrero@pre-tt.com
